Cell/Gene Tx channel feed

UniQure gets an­oth­er shot with he­mo­phil­ia gene ther­a­py af­ter FDA lifts clin­i­cal hold; Ne­oleuk­in's IL-2 hope­ful al­so cleared

5 years ago
FDA+

Bris­tol My­ers finds a home for 1st EU cell ther­a­py site, clear­ing land near Am­s­ter­dam air­port for easy lo­gis­tics

5 years ago
Manufacturing

Alde­vron founders back a biotech start­up that's look­ing to end the moral de­bate over cell lines once and for all

5 years ago
Startups

Blue­bird says it has more good news for its gene ther­a­py safe­ty, but a pric­ing dis­agree­ment in Ger­many will spur lay­offs

5 years ago

Near­ly a year af­ter Au­den­tes' gene ther­a­py deaths, the tri­al con­tin­ues. What hap­pened re­mains a mys­tery

5 years ago
In Focus

Gene ther­a­pies for neu­rode­gen­er­a­tive dis­eases: Pfiz­er, No­var­tis, Bio­gen and oth­ers seek more from FDA

5 years ago
FDA+

Taysha Gene Ther­a­pies gears up to ap­proach reg­u­la­tors with a new can­di­date for a de­bil­i­tat­ing neu­rode­gen­er­a­tive dis­ease

5 years ago
Deals

FDA and EMA sig­nal an op­por­tu­ni­ty to har­mo­nize ad­vanced ther­a­py reg­u­la­tions

5 years ago
FDA+

A pair of Lyell founders look to shift the cell ther­a­py par­a­digm — and they've got $30M to get their plan off the ground

5 years ago
Financing

Look­ing to lift clin­i­cal hold, uniQure con­tends its gene ther­a­py was like­ly not the cause of sin­gle liv­er can­cer case

5 years ago
FDA+

Ex­clu­sive: An in­dus­try con­sor­tium wants to stan­dard­ize cell track­ing for re­gen­er­a­tive meds. Could that avert a dis­as­ter?

5 years ago
Manufacturing

Step Phar­ma clos­es $41M round to take en­zyme tar­get­ing lead pro­gram in­to ear­ly-stage tri­al for T cell ma­lig­nan­cies

5 years ago
Financing

In­no­force gets $96M to build up Chi­na cam­pus, in­clud­ing a new Ther­mo Fish­er-part­nered mon­o­clon­al an­ti­body man­u­fac­tur­ing fa­cil­i­ty

5 years ago
Manufacturing

Xy­lo­Cor finds new back­ing to push re­gen­er­a­tive heart dis­ease gene ther­a­py deep­er in­to the clin­ic

5 years ago
Financing

CAR-M era be­gins as Caris­ma dos­es first pa­tient

5 years ago

An­oth­er blue­bird ex­ec jumps ship as ques­tions swirl over gene ther­a­pies and im­mi­nent split

5 years ago
People

Fresh out of the blue­bird bio on­col­o­gy split, Joanne Smith-Far­rell flies the coop to Be Bio and its B cell plat­form

5 years ago
People

Take­da, Sarep­ta dou­ble down on a biotech part­ner's plat­form to en­gi­neer bet­ter AAV cap­sids by map­ping out their struc­ture

5 years ago
Financing

Tai­wan's Ace­po­dia clos­es Se­ries B with the promise of con­ju­gat­ing an­ti­bod­ies and off-the-shelf NK cells

5 years ago
Financing

Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's not win­ning over in­vestors yet

5 years ago
R&D

Af­ter good news in sick­le cell, blue­bird bio fol­lows up with pos­i­tive long-term da­ta in Loren­zo’s Oil dis­ease

5 years ago

Next-gen gene edit­ing up­start is grab­bing the brass ring with a $150M crossover play to back its bid on a cure for sick­le cell dis­ease

5 years ago
Financing

El­e­vate­Bio adds an­oth­er $525M to its war chest as it looks to build on next-gen man­u­fac­tur­ing 'base­cam­p'

5 years ago
Financing
Manufacturing

Blue­bird ex­ecs ex­hale af­ter rul­ing sick­le cell ther­a­py 'very un­like­ly' to have caused AML event. How will FDA re­act?

5 years ago
First page Previous page 39404142434445 Next page Last page
A service from the Financial Times